Early Meetings Aid First-Cycle Approval If Sponsors Act, Consultants Tell FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NDA and BLA sponsors contribute to the need for multi-cycle reviews by failing to act on FDA recommendations made during development "milestone" meetings, according to an independent analysis of the agency’s first-cycle review performance.